Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SELLAS Life Sciences Group, Inc. (SLS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.14+3.04%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SLS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain strong cash position to fund operations | The company had $71.8 million cash at end 2025 to fund work. | Intact | Cash falls significantly below $71.8 million before key milestones | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Cash Position : As of June 30, 2026, cash and cash equivalents totaled approximately $138.3 million.” “Cash Position : As of March 31, 2026, cash and cash equivalents totaled approximately $107.1 million.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not an established earnings compounder. The multi-year view depends on clinical progress; the current thesis is on watch, with medium confidence and elevated risk.
The snapshot provides no valuation or market-expectations evidence, so whether SLS is cheap, fair, or expensive versus peers cannot be assessed. It also does not show what clinical success or failure the market already assumes.
Near term, results remain weak and loss-making: the latest reported quarterly net loss increased as research and development spending rose for trial preparations. Management is on track with enrollment and data milestones, and cash increased in the latest quarter after warrant exercises and capital raises. The next call, continued cash use, and the high-miss-rate industry remain risks.
The multi-year thesis hinges on clinical progress, including Phase 2 enrollment and the expected Q4 2026 topline data from the Phase 3 REGAL trial. Near term, guidance cuts or worsening economic conditions could weigh on the business, while strong results and higher guidance from healthcare peers may support sector momentum.
Over the next 1 to 3 years, SLS remains a high-risk clinical story with stated milestones advancing, but weak financial performance and trial outcomes are central uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advance clinical trial enrollment and topline data release | It aims to release clinical trial data by Q4 2026. | Under Pressure | Enrollment not started by Q1 2026 or topline data delayed beyond Q4 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage operating expenses and cash burn | A primary condition in SELLAS Life Sciences Group, Inc.'s published investment case. The stated target is Limit operating losses to no worse than negative $9.25 million per quarter. | Intact | Operating losses exceed negative $9.25 million per quarter persistently | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Overcome regulatory challenges from trial data | It aims to release clinical trial data by Q4 2026. | Under Pressure | REGAL trial data issues cause regulatory rejection or major delays | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.13 → $-0.10 · observed estimates
$0.05B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-25 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-26 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-27 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-28 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-29 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-30 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-07-31 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-01 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-02 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-03 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-04 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-05 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-06 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-08 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-09 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-10 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-12 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-13 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-14 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-15 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-16 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-17 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-18 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-19 | $-0.13 | $53,094,000 | 2 / 1 |
| 2026-08-20 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-21 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-22 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-23 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-24 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-25 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-26 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-27 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-28 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-29 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-30 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-08-31 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-01 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-02 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-03 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-04 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-05 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-06 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-07 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-08 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-09 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-10 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-11 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-12 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-13 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-14 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-15 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-16 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-17 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-18 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-19 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-20 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-21 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-22 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-23 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-24 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-25 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-26 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-27 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-28 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-29 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-09-30 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-01 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-02 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-03 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-04 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-05 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-06 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-07 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-08 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-09 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-10 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-11 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-12 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-13 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-14 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-15 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-16 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-17 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-18 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-19 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-20 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-21 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-22 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-23 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-24 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-25 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-26 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-27 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-28 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-29 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-30 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-10-31 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-11-01 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-11-02 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-11-03 | $-0.10 | $53,094,000 | 2 / 1 |
| 2026-11-04 | $-0.10 | $53,094,000 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.